Quadruple therapy for diabetic kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This study tests a combination of four medicines to see if they can better protect the kidneys in people with type 2 diabetes and kidney disease. It may help slow down kidney damage and reduce the amount of protein in urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have type 2 diabetes.
- You must be taking a standard blood pressure medicine (ACEI or ARB) for at least 1 month, and continue it during the study.
- Your body mass index (BMI) is 24 or higher.
- Your urine test shows a certain level of protein (albumin) between 100 and 5000 mg/g.
- Your kidney function (eGFR) is between 30 and 90, and your potassium level is 4.8 or lower.
- Your blood sugar control (HbA1c) is less than 11%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called finerenone can protect kidney function in people with type 2 diabetes and early-to-moderate chronic kidney disease. It may be an option if you are already on blood pressure medication and have some protein in your urine.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This study looks at whether starting four recommended medications all at once—instead of one by one—is safe and better for protecting the kidneys in people with type 2 diabetes and early kidney damage. You would receive all four medicines together and be closely monitored by the study team.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
This study tests whether a goal-directed treatment plan using several medications can lower the risk of kidney and heart problems for people with diabetes and kidney disease. It aims to help you manage your condition more effectively.
Hear when a new Type 2 Diabetic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.